EUVIMEDEUVIMED entdecken
Open Access

De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy

Min Chul Kim, Sung Gyun Ahn, Kyung Hoon Cho, Doo Sun Sim, Young Joon Hong, Ju Han Kim, Myung Ho Jeong, Jun-Won Lee, Young-Jin Youn, Hee-Yeol Kim, Ki-Dong Yoo, Doo-Soo Jeon und 4 weitere

EuroIntervention · 2023

DOI: 10.4244/eij-d-23-00427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EuroIntervention, 2023. Verfasst von Min Chul Kim und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, S…. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The benefits of de-escalation of P2Y12 inhibition after percutaneous coronary intervention (PCI) may differ by high bleeding risk (HBR) status. AIMS: We investigated the efficacy and safety of de-escalation from ticagrelor to clopidogrel after PCI by HBR status. METHODS: This is a non-prespecified post hoc analysis of the TicAgrelor Versus CLOpidogrel in Stabilized Patients with Acute Myocardial Infarction (TALOS-AMI) trial. Net adverse clinical events (a composite of cardiovascular death, myocardial infarction, stroke, or Bleeding Academic Research Consortium [BARC] bleeding type 2, 3, or 5) at 1 year post-PCI were compared between the de-escalation (clopidogrel plus aspirin) and the active control (ticagrelor plus aspirin) groups by HBR status, as defined by the modification of the Academic Research Consortium (ARC) criteria. RESULTS: A total of 2,625 patients in the TALOS-AMI trial were analysed. Of these, 589 (22.4%) met the modified ARC-HBR criteria. The de-escalation group had lower primary endpoint rates than the control group in both HBR (hazard ratio [HR] 0.47, 95% confidence interval [CI]: 0.26-0.84) and non-HBR (HR 0.59, 95% CI: 0.41-0.84) patients. There were no differences in treatment effect for the primary endpoint regardless of HBR status (p for interaction=0.904). BARC bleeding type 3 or 5 was less common in the de-escalation than the control group among HBR patients only (HR 0.24, 95% CI: 0.07-0.84). CONCLUSIONS: In stabilised acute myocardial infarction patients, unguided de-escalation from ticagrelor to clopidogrel was associated with a lower rate of net adverse clinical outcomes irrespective of HBR status. The effect of de-escalation of P2Y12 inhibition on reducing haemorrhagic events was greater in patients with HBR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionAcute Coronary SyndromeMyocardial InfarctionHumansClopidogrelTicagrelorPlatelet Aggregation InhibitorsHemorrhageAspirinTreatment Outcome

Substanzen

ClopidogrelTicagrelorPlatelet Aggregation InhibitorsAspirin

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.
  • Division of Cardiology, Department of Internal Medicine, Wonju Severance Christian Hospital, Wonju, South Korea.
  • Division of Cardiology, Department of Internal Medicine, Bucheon St Mary's Hospital, Bucheon, South Korea.
  • Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea, St Vincent's Hospital, Suwon, South Korea.
  • Division of Cardiology, Department of Internal Medicine, Incheon St Mary's Hospital, Incheon, South Korea.
  • Division of Cardiology, Department of Internal Medicine, Ulsan University Hospital, Ulsan, South Korea.

Zitieren

APA

Kim, M. C., Ahn, S. G., Cho, K. H., Sim, D. S., Hong, Y. J., Kim, J. H., Jeong, M. H., Lee, J. W., Youn, Y. J., Kim, H. Y., Yoo, K. D., Jeon, D. S., Shin, E. S., Jeong, Y. H., Chang, K., & Ahn, Y. (2023). De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy. EuroIntervention. https://doi.org/10.4244/eij-d-23-00427

Vancouver

Kim MC, Ahn SG, Cho KH, Sim DS, Hong YJ, Kim JH, et al. De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy. EuroIntervention. 2023. doi:10.4244/eij-d-23-00427

BibTeX
@article{Kim2023,
  author = {Kim, Min Chul and Ahn, Sung Gyun and Cho, Kyung Hoon and Sim, Doo Sun and Hong, Young Joon and Kim, Ju Han and Jeong, Myung Ho and Lee, Jun-Won and Youn, Young-Jin and Kim, Hee-Yeol and Yoo, Ki-Dong and Jeon, Doo-Soo and Shin, Eun-Seok and Jeong, Young-Hoon and Chang, Kiyuk and Ahn, Youngkeun},
  title = {De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy},
  journal = {EuroIntervention},
  year = {2023},
  doi = {10.4244/eij-d-23-00427}
}
Kostenlos starten →